We are live on ! Find out more
BLRX

BioLineRX
BLRX

15 hedge funds and large institutions have $6.74M invested in BioLineRX in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0.04% → 0.04% (-0%)

38% less funds holding

Funds holding: 24 → 15 (-9)

51% less capital invested

Capital invested by funds: $13.9M → $6.74M (-$7.11M)

62% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 13

Holders
15
Holders Change
-9
Holders Change %
-37.5%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
2
Reduced
–
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$175K
2
EMG
ETF Managers Group
New Jersey
+$166K
3
NFG
Next Financial Group
Texas
+$9.15K
4
UBS Group
UBS Group
Switzerland
+$3.75K
5
ADL
Asset Dedication LLC
California
+$1.25K

Top Sellers

Rank Fund Capital Flow
1
FI
Fosun International
China
-$263K
2
SAM
Sectoral Asset Management
Quebec, Canada
-$65K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$31K
4
CCB
Cutter & Co Brokerage
Missouri
-$21K
5
MCC
Malaga Cove Capital
California
-$9K
Name Holding Trade Value Shares
Change 		Change in
Stake
FWM
26
Focused Wealth Management
New York
– -$2K -8 Closed
DWM
27
Doyle Wealth Management
Florida
– -$1K -5 Closed
1
2

BLRX Hedge Fund Activity: Q3 2019 in Review

15 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q3 2019, worth a combined $6.74M — down 51% from $13.9M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of BLRX and 5 opened new positions — a net loss of 8 holders — while 0 trimmed existing stakes and 2 added.

The largest buyer was Morgan Stanley, adding an estimated $175K. The largest seller was Fosun International, exiting entirely with an estimated $263K sold.

  • 15 institutional investors held BioLineRX (BLRX) as of Q3 2019, down from 24 in Q2 2019.
  • Funds reported $6.74M of BioLineRX stock for Q3 2019, down 51% quarter-over-quarter.
  • 5 funds opened new BioLineRX positions in Q3 2019 and 13 closed out, a net change of -8 holders.
  • The largest BioLineRX buyer in Q3 2019 was Morgan Stanley, an estimated $175K added.
  • The largest BioLineRX seller in Q3 2019 was Fosun International, an estimated $263K sold.

Based on aggregated 13F filings for Q3 2019.